VLA-4 inhibitor compounds
View Patent ↗Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.
1. A compound represented by Formula I, or a salt thereof,
wherein
W is chosen from aryl group, substituted aryl group, heteroaryl group and substituted heteroaryl group;
W 1 is chosen from arylene group, substituted arylene group, heteroarylene group and substituted heteroarylene group;
A is chosen from ═O, ═S and ═NH;
R is chosen from a direct bond, alkenylene group and —(CH 2 ) n —,
wherein
n is chosen from 1 and 2;
X is chosen from —C(O)—, —CH 2 — and S(O) 2 ;
M is chosen from
is a divalent thiazolidine moiety, wherein the nitrogen atom is the point of attachment to X;
R 1 , R 2 and R 3 are independently chosen from —H, —OH, —NH 2 , halogen atom, alkyl group, substituted alkyl group, aryl group, substituted aryl group, alkoxy group, substituted alkoxy group, monoalkylamino group, substituted monoalkylamino group, dialkylamino group, substituted dialkylamino group, cycloalkylamino group, substituted cycloalkylamino group, alkylsulfonylamino group, substituted alkylsulfonylamino group, arylsulfonylamino group, substituted arylsulfonylamino group, aryloxy group, substituted aryloxy group, heteroaryloxy group, substituted heteroaryloxy group, benzyloxy group and substituted benzyloxy group;
R 4 is chosen from —H and lower alkyl group;
Y is a direct bond or a divalent radical chosen from —C(O)—, —C(O)NH—, alkenylene group, alkynylene group and —(CH 2 ) k Y 2 ,
wherein
k is chosen from 1, 2 and 3; and
Y 2 is a direct bond or a divalent radical chosen from —O—, —S—, —S(O), —S(O) 2 — and —NY 3 —,
wherein
Y 3 is chosen from —H and lower alkyl group;
Z is chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group, with the proviso that when Y is a direct bond, Z is not a five-membered substituted or unsubstituted nitrogen-containing heterocyclylene group;
A 1 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group, —(CH 2 ) t — and —O(CH 2 ) v ,
wherein
t is chosen from 1, 2 and 3; and
v is chosen from 0, 1, 2, and 3; and
R 5 is chosen from —OH, lower alkoxy group, —N(H)OH,
is a divalent thiazolidine moiety, wherein the nitrogen atom is the point of attachment to X;
R 6 and R 7 are independently chosen from —H, —OH, halogen atom, alkyl group and alkoxy group;
Y 1 is a divalent radical chosen from —O—, —S—, —S(O)—, —S(O) 2 — and —NY 4 —,
wherein
Y 4 is chosen from —H and lower alkyl group;
Z 1 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group;
A 2 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group and —(CH 2 ) e
wherein
e is chosen from 1, 2and 3; and
R 8 is chosen from —OH, lower alkoxy group, —N(H)OH,
L is
wherein
is a divalent thiazolidine moiety, wherein the nitrogen atom is the point of attachment to X, optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, alkoxy group, hydroxyalkyl group, —OH, benzyloxy group, —NH 2 , halogen atom, aryl group and heteroaryl group;
m and q are independently chosen from 0, 1, 2 and 3;
X 1 is chosen from —CH═ and —N═;
R 9 is chosen from —H and lower alkyl group;
R 10 is chosen from —COOH, lower alkoxycarbonyl group,
Z 2 is chosen from —H, COOH and lower alkoxycarbonyl group.
2. A compound according to claim 1 , or a salt thereof, wherein M is
3. A compound according to claim 1 , or a salt thereof, wherein M is
4. A compound according to claim 1 , or a salt thereof, wherein M is
5. A compound according to claim 2 , or a salt thereof, wherein at least one radical of R 1 , R 2 and R 3 is —OH or halogen atom.
6. A compound according to claim 5 , or a salt thereof, wherein A is ═O, R is —(CH 2 ) n — and X is —C(O)—.
7. A compound according to claim 6 , or a salt thereof, wherein Y is chosen from alkenylene group, alkynylene group and —(CH 2 ) k Y 2 ; Y 2 is chosen from a direct bond, —O—, —S(O) and —NY 3 —; and Y 3 is —H.
8. A compound according to claim 7 , or a salt thereof, wherein Y is chosen from —O— and —NY 3 —.
9. A compound according to claim 2 , or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof.
10. A compound according to claim 9 , or a salt thereof, wherein W 1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof.
11. A compound according to claim 2 , or a salt thereof, wherein W 1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof and having 1 to 3 substituents chosen from lower alkyl group and halogen atom.
12. A compound according to claim 2 , or a salt thereof, wherein A 1 is a direct bond or —(CH 2 ) t —.
13. A compound according to claim 12 , or a salt thereof, wherein A 1 is a direct bond.
14. A compound according to claim 13 , or a salt thereof, wherein R 5 is —OH.
15. A compound according to claim 2 , or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof; W 1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the —NH— thereof; R is —CH 2 —; X is —C(O)— and R 5 is —OH.
16. A compound according to claim 2 , or a salt thereof, wherein R 5 is lower alkoxy group.
17. A compound according to claim 15 , or a salt thereof, chosen from the group consisting of
18. A compound according to claim 17 , or a salt thereof which is
19. A pharmaceutical composition comprising as a therapeutic agent, a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.
20. A pharmaceutical composition according to claim 19 , further comprising one or more additional therapeutic agents.
21. A pharmaceutical composition according to claim 20 , wherein said one or more additional therapeutic agents are chosen from the group consisting of antiinflammatory, antirheumatic, corticosteroid, immunosuppressive, antipsoriatic, bronchodilator, antiasthmatic and antidiabetic agents.
22. A pharmaceutical composition according to claim 21 , wherein one of said one or more additional therapeutic agents is an antiinflammatory agent.
23. A pharmaceutical composition according to claim 22 , wherein said antiinflammatory agent is chosen from a steroid and an NSAID.
24. A method of treating a condition associated with VLA-4 mediated cell adhesion in a mammal, said condition being selected from asthma and arthritis, said method comprising administering to said mammal an effective amount of a compound according to claim 1 .